Michael Cilento
School of Medicine
College of Health
Dr Michael Cilento MBBS FRACP is a medical oncologist and PhD candidate in the Prostate Cancer Research Group at the South Australian Health and Medical Research Institute (SAHMRI). Dr Cilento received his medical degree from the University of Adelaide and did his residency at the Royal Adelaide Hospital. He completed his oncology training in South Australia, which was followed by a fellowship in early drug development and phase 1 clinical trials at the Peter MacCallum Cancer Centre Melbourne. Dr Cilento joined Flinders Centre for Innovation in Cancer in 2024. He then returned to the Royal Adelaide Hospital as a consultant medical oncologist in 2025. Dr Cilento's PhD research is utilising spatial profiling methods to identify novel metabolic drivers of lethal prostate cancer.
| Year | Citation |
|---|---|
| 2025 | Cilento, M. A., Butler, L. M., Emmett, L., & Sweeney, C. J. (2025). Personalized intensification of treatment for hormone-sensitive prostate cancer. NATURE REVIEWS CLINICAL ONCOLOGY, 16 pages. |
| 2024 | Cilento, M. A., Sweeney, C. J., & Butler, L. M. (2024). Spatial transcriptomics in cancer research and potential clinical impact: a narrative review. Journal of Cancer Research and Clinical Oncology, 150(6), 296-1-296-16. Scopus21 WoS19 Europe PMC19 |
| 2022 | Cilento, M. A., Klein, O., Egan, E., & Roberts‐Thomson, R. (2022). Talimogene laherparepvec resulting in near‐complete response in a patient with treatment‐refractory Merkel cell carcinoma. Australasian Journal of Dermatology, 63(3), e222-e225. Scopus9 WoS8 Europe PMC6 |
| 2022 | Cilento, M. A., Kim, C., Chang, S., Farshid, G., & Brown, M. P. (2022). Three cases of BRAF-mutant melanoma with divergent differentiation masquerading as sarcoma.. Pathologica, 114(3), 217-220. Scopus7 WoS7 Europe PMC5 |
| 2021 | Cilento, M. A., & Hocking, C. M. (2021). Cystic and cavitating lung lesions as a presenting finding of metastatic prostate cancer. Medical Journal of Australia, 214(10), 459-459.e1. Scopus2 WoS1 Europe PMC1 |
| 2021 | Cilento, M. A., Poplawski, N. K., Paramasivam, S., Thomas, D. M., & Kichenadasse, G. (2021). Germline PALB2 variants and PARP inhibitors in endometrial cancer. Jnccn Journal of the National Comprehensive Cancer Network, 19(11), 1212-1217. Scopus8 WoS7 Europe PMC8 |
| Year | Citation |
|---|---|
| 2023 | Cilento, M. A., Mah, C. Y., Martelotto, L., Sweeney, C. J., & Butler, L. M. (2023). Multiomic analysis workflow for biomarker discovery in human prostate cancer. Poster session presented at the meeting of ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. WILEY. |
| 2022 | Cilento, M. A., Chalwin, R., Hocking, C., Chan, L., Smithers, L., & Joshi, R. (2022). MORBIDITY AND MORTALITY OF ONCOLOGY PATIENTS ADMITTED TO AN INTENSIVE CARE UNIT. Poster session presented at the meeting of INTERNAL MEDICINE JOURNAL. WILEY. |
| 2021 | Cilento, M., & Roberts-Thomson, R. (2021). Weight changes during adjuvant nivolumab for resected melanoma. Poster session presented at the meeting of Poster Abstracts. Asia-Pacific Journal of Clinical Oncology, 17: 110-208.. Virtual. DOI |
Connect With Me
External Profiles
